CLOs on the Move

Landmark Bio

www.landmarkbio.com

 
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Michael Covington
Chief Quality and Regulatory Officer Profile

Similar Companies

Hays Life Sciences

Hays Life Sciences is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fytokem Products

Fytokem Products Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Accelerated Genetics

Accelerated Genetics is a Baraboo, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NephroGenex

NephroGenex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Castle Biosciences

Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.